Marc Goodman
Stock Analyst at Leerink Partners
(3.58)
# 953
Out of 4,479 analysts
82
Total ratings
51.25%
Success rate
21%
Average return
Main Sectors:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $17.54 | +82.44% | 1 | Apr 15, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: Market Perform | n/a | $1.74 | - | 4 | Mar 11, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $45.50 | -45.05% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $21.74 | +129.99% | 1 | Jan 30, 2023 | |
| BHVN Biohaven Pharmaceutical Holding Company | Initiates: Outperform | $24 | $34.17 | -29.76% | 4 | Jan 24, 2023 | |
| RLMD Relmada Therapeutics | Maintains: Outperform | $42 → $10 | $2.99 | +234.45% | 2 | Jan 23, 2023 | |
| MRNS Marinus Pharmaceuticals | Maintains: Outperform | $27 → $23 | $1.19 | +1,832.77% | 4 | Jan 23, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $10.66 | +87.62% | 2 | Jan 19, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $65 → $85 | $78.93 | +7.69% | 5 | Nov 29, 2022 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $137.49 | -16.36% | 3 | Nov 2, 2022 | |
| BIIB Biogen | Maintains: Outperform | $270 → $310 | $228.82 | +35.48% | 10 | Oct 26, 2022 | |
| ELYM Eliem Therapeutics | Maintains: Outperform | $9 → $4 | $6.81 | -41.26% | 4 | Aug 16, 2022 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $6 → $12 | $13.89 | -13.61% | 2 | Aug 11, 2022 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $40 → $46 | $36.56 | +25.82% | 4 | Aug 11, 2022 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $27 → $21 | $15.84 | +32.58% | 3 | Aug 9, 2022 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $200 → $210 | $105.09 | +99.83% | 5 | Aug 4, 2022 | |
| SAGE Sage Therapeutics | Maintains: Market Perform | $50 → $40 | $10.82 | +269.69% | 4 | Jul 11, 2022 | |
| ACIU AC Immune | Maintains: Outperform | $15 → $10 | $3.87 | +158.40% | 2 | Jul 11, 2022 | |
| ALKS Alkermes | Maintains: Market Perform | $24 → $27 | $24.19 | +11.62% | 4 | Apr 28, 2022 | |
| OPT Opthea | Initiates: Outperform | $25 | $1.93 | +1,198.70% | 1 | Apr 26, 2022 | |
| ITCI Intra-Cellular Therapies | Maintains: Outperform | $65 → $70 | $68.54 | +2.13% | 3 | Apr 21, 2022 | |
| ALDX Aldeyra Therapeutics | Maintains: Outperform | $24 → $15 | $3.25 | +361.54% | 2 | Dec 21, 2021 | |
| ABBV AbbVie | Assumes: Neutral | n/a | $165.96 | - | 3 | Jan 23, 2019 | |
| ULTA Ulta Beauty | Maintains: Buy | n/a | $393.02 | - | 3 | Dec 7, 2018 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | n/a | $40.45 | - | 2 | May 21, 2018 | |
| MRK Merck & Co. | Maintains: Buy | n/a | $127.72 | - | 2 | Oct 30, 2017 | |
| PRGO Perrigo Company | Maintains: Buy | n/a | $25.99 | - | 1 | Oct 5, 2017 |
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $17.54
Upside: +82.44%
Amylyx Pharmaceuticals
Mar 11, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.74
Upside: -
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $45.50
Upside: -45.05%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $21.74
Upside: +129.99%
Biohaven Pharmaceutical Holding Company
Jan 24, 2023
Initiates: Outperform
Price Target: $24
Current: $34.17
Upside: -29.76%
Relmada Therapeutics
Jan 23, 2023
Maintains: Outperform
Price Target: $42 → $10
Current: $2.99
Upside: +234.45%
Marinus Pharmaceuticals
Jan 23, 2023
Maintains: Outperform
Price Target: $27 → $23
Current: $1.19
Upside: +1,832.77%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $10.66
Upside: +87.62%
Axsome Therapeutics
Nov 29, 2022
Maintains: Outperform
Price Target: $65 → $85
Current: $78.93
Upside: +7.69%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $137.49
Upside: -16.36%
Biogen
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $228.82
Upside: +35.48%
Eliem Therapeutics
Aug 16, 2022
Maintains: Outperform
Price Target: $9 → $4
Current: $6.81
Upside: -41.26%
Avadel Pharmaceuticals
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $13.89
Upside: -13.61%
Xenon Pharmaceuticals
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $36.56
Upside: +25.82%
ACADIA Pharmaceuticals
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $15.84
Upside: +32.58%
Jazz Pharmaceuticals
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $105.09
Upside: +99.83%
Sage Therapeutics
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $10.82
Upside: +269.69%
AC Immune
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.87
Upside: +158.40%
Alkermes
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $24.19
Upside: +11.62%
Opthea
Apr 26, 2022
Initiates: Outperform
Price Target: $25
Current: $1.93
Upside: +1,198.70%
Intra-Cellular Therapies
Apr 21, 2022
Maintains: Outperform
Price Target: $65 → $70
Current: $68.54
Upside: +2.13%
Aldeyra Therapeutics
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $3.25
Upside: +361.54%
AbbVie
Jan 23, 2019
Assumes: Neutral
Price Target: n/a
Current: $165.96
Upside: -
Ulta Beauty
Dec 7, 2018
Maintains: Buy
Price Target: n/a
Current: $393.02
Upside: -
Bristol-Myers Squibb Company
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $40.45
Upside: -
Merck & Co.
Oct 30, 2017
Maintains: Buy
Price Target: n/a
Current: $127.72
Upside: -
Perrigo Company
Oct 5, 2017
Maintains: Buy
Price Target: n/a
Current: $25.99
Upside: -